Search | Page 22 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trials Report for April 2014

    ... NCT02085408 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care ... A Phase 3 evaluation of the Efficacy and Safety of oral Azacitidine plus best supportive care versus placebo and best supportive care ...

    Page last updated 04/18/2014 - 3:36pm.

  2. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... with the commonly used hypomethylating agents (HMA), azacitidine (Vidaza®), and decitabine (Dacogen®)? The ... the mechanisms of action is for the two HMA drugs.  Both 5-azacitidine and deoxy-azacitdine are thought to cause reversal of DNA ...

    Interview last updated 06/17/2014 - 9:15am.

  3. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... and applied it specifically to patients who were on azacitidine (Vidaza®). This is important because both the IPSS and IPSS-R ... be used to predict survival in patients who are treated with azacitidine, thus it is valid for a patient who is about to start azacitidine ...

    Interview last updated 02/07/2013 - 1:28pm.

  4. Aplastic Anemia and MDS Overlap Syndrome

    ... the standard of care should be hypomethylating agents, azacitidine (Vidaza®) and decitabine (Dacogen®), which of course ...

    Interview last updated 05/13/2015 - 8:37am.

  5. MDS and MDS/MPN: Past, Present, and Future 2014 American Society of Hematology (ASH) Satellite Symposium Summary for Patients and Families

    ... protein formation). The hypomethylating agents (HMAs) azacitidine (Vidaza®) and decitabine (Dacogen®) inhibit DNA ...

    Page last updated 03/13/2015 - 5:00pm.

  6. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... low blood counts that often occur when treatment with azacitidine (Vidaza®) is started, there could be serious complications, ... even more difficult to treat with standard therapies such as azacitidine (Vidaza®) or lenalidomide (Revlimid®). The more things that are ...

    Interview last updated 11/17/2014 - 9:31am.

  7. Clinical Trial Basics

    ... (Revlimid) eculizumab (Soliris) azacitidine (Vidaza) eltrombopag (Promacta) Research has also ...

    Page last updated 01/20/2015 - 4:58pm.

  8. Clinical Trial Basics

    ... (Revlimid) eculizumab (Soliris) azacitidine (Vidaza) eltrombopag (Promacta) Research has also ...

    Page last updated 01/20/2015 - 4:46pm.

  9. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... agents, which are the two FDA-approved drugs azacitidine (Vidaza®) anddecitabine (Dacogen®). These are the primary ...

    Interview last updated 09/22/2014 - 12:25pm.

  10. Treating Higher-Risk Myelodysplastic Syndromes

    ... cell transplant, may be hypomethylating agents like azacitidine (Vidaza®) or decitabine (Dacogen®). If patients have ... The current standard of care treatments for MDS includes azacitidine, decitabine, or lenalidomide (Revlimid®). ...

    Interview last updated 05/18/2012 - 1:55pm.